Jacc: Cardiooncology最新文献

{"title":"Atherosclerotic Cardiovascular Diseases Are Associated With Incident Metastatic and Nonmetastatic Cancer","authors":"Tal Caller MSc ,&nbsp;Alexander Fardman MD ,&nbsp;Yariv Gerber PhD ,&nbsp;Yonatan Moshkovits BSc ,&nbsp;Shmuel Tiosano MD ,&nbsp;Alon Kaplan BSc ,&nbsp;Maia Kalstein BSc ,&nbsp;Gabriella Bayshtok BSc ,&nbsp;Tomer Itkin PhD ,&nbsp;Abraham Avigdor MD ,&nbsp;Nili Naftali-Shani PhD ,&nbsp;Jonathan Leor MD ,&nbsp;Elad Maor MD, PhD","doi":"10.1016/j.jaccao.2024.07.020","DOIUrl":"10.1016/j.jaccao.2024.07.020","url":null,"abstract":"<div><h3>Background</h3><div>Cardiovascular diseases are associated with higher cancer risk. However, their relationship with metastatic cancer, the primary determinant of cancer prognosis, has not been studied.</div></div><div><h3>Objectives</h3><div>This study aimed to determine the association between atherosclerotic cardiovascular disease and the presence of metastasis at the time of cancer diagnosis.</div></div><div><h3>Methods</h3><div>We analyzed data from 21,654 self-referred adults who were free of cancer and atherosclerotic cardiovascular disease at enrollment in a preventive health care program. To exclude silent cancers, a 1-year blanking period was implemented at the start of the follow-up. The relationship between atherosclerotic cardiovascular disease and metastatic cancer was assessed using cause-specific Cox regression, treating incident atherosclerotic cardiovascular disease as a time-dependent covariate. Interaction analysis further elucidated differences in metastasis risks between middle-aged adults (Q1-Q3 age ≤54 years) and older adults (Q4 age &gt;54 years).</div></div><div><h3>Results</h3><div>Over a median follow-up of 6 years (Q1-Q3: 3-12 years), we recorded 1,333 cases of atherosclerotic cardiovascular disease (6.2%) and 1,793 cases of cancer (8.3%), of which 1,036 (4.8 %) were nonmetastatic and 757 (3.5%) were metastatic at diagnosis. After adjusting for shared risk factors, atherosclerotic cardiovascular disease was independently associated with an increased risk of cancer metastasis at the time of cancer diagnosis (HR: 1.75; 95% CI: 1.33-2.29). This association was more pronounced among middle-aged adults (HR: 1.64; 95% CI: 1.03-2.61; <em>P</em> = 0.036) than in older adults (HR: 1.11; 95% CI: 0.78-1.60; <em>P</em> = 0.56), with a significant interaction (<em>P</em>_interaction = 0.039).</div></div><div><h3>Conclusions</h3><div>Atherosclerotic cardiovascular disease is associated with a significantly increased risk of cancer, specifically metastasis at the time of cancer diagnosis, particularly in middle-aged adults. Recognizing this association could enhance the prevention and treatment of metastatic cancer in patients with atherosclerotic cardiovascular disease.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 949-961"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Prevention and Early Detection in Patients With Cardiovascular Disease","authors":"Pietro Ameri MD, PhD ,&nbsp;Susan Dent MD","doi":"10.1016/j.jaccao.2024.09.009","DOIUrl":"10.1016/j.jaccao.2024.09.009","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 962-964"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Net Clinical Benefit of 12-Month Over 3-Month Edoxaban in Cancer-Associated Isolated Distal Deep Vein Thrombosis","authors":"Yuji Nishimoto MD ,&nbsp;Yugo Yamashita MD ,&nbsp;Takeshi Morimoto MD, MPH ,&nbsp;Nao Muraoka MD ,&nbsp;Michihisa Umetsu MD ,&nbsp;Takuma Takada MD ,&nbsp;Yoshito Ogihara MD ,&nbsp;Tatsuya Nishikawa MD ,&nbsp;Nobutaka Ikeda MD ,&nbsp;Yukihito Sato MD ,&nbsp;Takahisa Yamada MD ,&nbsp;Takeshi Kimura MD ,&nbsp;ONCO DVT Study Investigators","doi":"10.1016/j.jaccao.2024.07.019","DOIUrl":"10.1016/j.jaccao.2024.07.019","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 979-981"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2 Inhibitors in Mitigating Cancer Therapy-Related Cardiac Dysfunction","authors":"Mohamed S. Dabour MS ,&nbsp;Anne H. Blaes MD, MS ,&nbsp;Bhavadharini Ramu MD ,&nbsp;Beshay N. Zordoky MS, PhD","doi":"10.1016/j.jaccao.2024.10.005","DOIUrl":"10.1016/j.jaccao.2024.10.005","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 876-878"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Diagnosis, Physical Activity, and Heart Disease Risk","authors":"Emmanuel Stamatakis PhD ,&nbsp;Nicholas A. Koemel PhD ,&nbsp;Raaj K. Biswas PhD ,&nbsp;Matthew N. Ahmadi PhD","doi":"10.1016/j.jaccao.2024.11.002","DOIUrl":"10.1016/j.jaccao.2024.11.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 890-892"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11712014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Considerations During Cancer Therapy","authors":"Darryl P. Leong MBBS, MPH, MBiostat, PhD ,&nbsp;Sarah Waliany MD, MS ,&nbsp;Husam Abdel-Qadir MD, PhD ,&nbsp;Katelyn M. Atkins MD, PhD ,&nbsp;Tomas G. Neilan MD, MPH ,&nbsp;Ninian N. Lang MB ChB, PhD ,&nbsp;Jennifer E. Liu MD ,&nbsp;Anne H. Blaes MD, MS ,&nbsp;Hira S. Mian MD ,&nbsp;Heather N. Moore PharmD, BCOP, CPP ,&nbsp;Ludhmila A. Hajjar MD ,&nbsp;Alicia K. Morgans MD, MPH ,&nbsp;Peter M. Ellis MBBS, MMed, PhD ,&nbsp;Susan Dent MD","doi":"10.1016/j.jaccao.2024.06.005","DOIUrl":"10.1016/j.jaccao.2024.06.005","url":null,"abstract":"<div><div>The administration of certain cancer therapies can be associated with the development of cardiovascular toxicity or complications. This spectrum of toxicities is broad and requires nuanced approaches for prevention, identification, and management. This expert panel summarizes the consensus of opinions of diverse health care professionals in several key areas: 1) cardioprotection involves strategies aimed at the primary prevention of cancer therapy–related cardiovascular toxicity; 2) surveillance entails monitoring for cancer therapy–related cardiovascular toxicity during cancer therapy; 3) permissive cardiotoxicity is the informed continuation of cancer therapy in the presence of cardiovascular toxicity, along with the implementation of mitigating cardiovascular treatments; and 4) special considerations include the invasive management of severe cardiovascular disease in patients receiving treatments for advanced cancer and the exploration of drug-drug interactions in cardio-oncology. In this expert panel, we also highlight gaps in evidence in an effort to continue to advance science in the cardiovascular care of our patients undergoing cancer therapy.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 815-834"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elucidating the Signal from the Noise","authors":"Florence K. Keane MD ,&nbsp;Tomas G. Neilan MD, MPH ,&nbsp;Rachel B. Jimenez MD","doi":"10.1016/j.jaccao.2024.10.007","DOIUrl":"10.1016/j.jaccao.2024.10.007","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 946-948"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses","authors":"Francesco Angeli MD ,&nbsp;Francesca Bodega MD ,&nbsp;Luca Bergamaschi MD ,&nbsp;Matteo Armillotta MD ,&nbsp;Sara Amicone MD ,&nbsp;Lisa Canton MD ,&nbsp;Damiano Fedele MD ,&nbsp;Nicole Suma MD ,&nbsp;Daniele Cavallo MD ,&nbsp;Alberto Foà MD, PhD ,&nbsp;Marta Belmonte MD ,&nbsp;Vincenzo Russo MD ,&nbsp;Domenico Attinà MD ,&nbsp;Fabio Niro MD ,&nbsp;Rachele Bonfiglioli MD ,&nbsp;Stefano Fanti MD ,&nbsp;Anna Giulia Pavon MD ,&nbsp;Marco Guglielmo MD ,&nbsp;Saima Mushtaq MD ,&nbsp;Maria Abbondanza Pantaleo MD ,&nbsp;Carmine Pizzi MD","doi":"10.1016/j.jaccao.2024.09.006","DOIUrl":"10.1016/j.jaccao.2024.09.006","url":null,"abstract":"<div><div>Cardiac masses encompass a diverse range of benign and malignant tumors as well as pseudotumors. Accurate histologic identification is essential for guiding appropriate treatment, yet the diagnostic process remains challenging. Although biopsy is traditionally the diagnostic gold standard, its invasive nature and associated risks limit its application. A noninvasive multimodality imaging approach has recently emerged as an alternative, but standardized protocols and supporting evidence are still lacking. Echocardiography is typically the initial imaging modality, with cardiac magnetic resonance recognized as the noninvasive diagnostic gold standard. Cardiac computed tomography provides complementary data to aid in diagnosis and management, while positron emission tomography serves as a third-level imaging option. This state-of-the-art review highlights the role of current multimodality imaging techniques in diagnosing and managing cardiac masses and explores future directions for their applications.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 847-862"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes","authors":"Ammar W. Bhatti DO ,&nbsp;Rushin Patel MD ,&nbsp;Sourbha S. Dani MD ,&nbsp;Sumanth Khadke MD ,&nbsp;Bhargav Makwana MD ,&nbsp;Candace Lessey MD ,&nbsp;Jui Shah MD ,&nbsp;Zaid Al-Husami MD ,&nbsp;Eric H. Yang MD ,&nbsp;Paaladinesh Thavendiranathan MD, SM ,&nbsp;Tomas G. Neilan MD ,&nbsp;Diego Sadler MD ,&nbsp;Richard K. Cheng MD, MSc ,&nbsp;Susan F. Dent MD ,&nbsp;Jennifer Liu MD ,&nbsp;Teresa Lopez-Fernandez MD ,&nbsp;Joerg Herrmann MD ,&nbsp;Marielle Scherrer-Crosbie MD, PhD ,&nbsp;Daniel J. Lenihan MD ,&nbsp;Salim S. Hayek MD ,&nbsp;Sarju Ganatra MD","doi":"10.1016/j.jaccao.2024.08.001","DOIUrl":"10.1016/j.jaccao.2024.08.001","url":null,"abstract":"<div><h3>Background</h3><div>Specific cancer treatments can lead to cancer therapy–related cardiac dysfunction (CTRCD). Sodium glucose cotransporter-2 inhibitors (SGLT2is) can potentially prevent these cardiotoxic effects.</div></div><div><h3>Objectives</h3><div>This study sought to determine whether SGLT2i use is associated with a lower incidence of CTRCD in patients with type 2 diabetes mellitus (T2DM) and cancer, exposed to potentially cardiotoxic antineoplastic agents, and without a prior documented history of cardiomyopathy or heart failure.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of patients aged ≥18 years within the TriNetX database with T2DM, cancer, exposure to cardiotoxic therapies, and no prior documented history of cardiomyopathy or heart failure. Patients were categorized by SGLT2i use. After propensity score matching, outcomes were compared over 12 months using Cox proportional HRs. Subgroup analyses focusing on different cancer therapy classes were performed.</div></div><div><h3>Results</h3><div>The study included 8,675 propensity-matched patients in each cohort (mean age = ∼65 years, 42% females, 71% White, ∼19% gastrointestinal malignancy, and ∼25% anthracyclines). Patients prescribed SGLT2is had a lower risk of developing CTRCD (HR: 0.76: 95% CI: 0.69-0.84). SGLT2is also reduced heart failure exacerbations (HR: 0.81; 95% CI: 0.72-0.90), all-cause mortality (HR: 0.67; 95% CI: 0.61-0.74), and all-cause hospitalizations/emergency department visits (HR: 0.93; 95% CI: 0.89-0.97). Subgroup analyses also demonstrated reduced CTRCD risk across various classes of cancer therapies in patients prescribed SGLT2is.</div></div><div><h3>Conclusions</h3><div>SGLT2i administration was associated with a significantly decreased risk of developing CTRCD in patients with T2DM and cancer.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 863-875"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep Inspiration Breath Hold to Reduce Cardiovascular Disease Risk for Breast Radiotherapy","authors":"Shanshan Gao MD ,&nbsp;Jian Zhang MD ,&nbsp;Beina Hui MD ,&nbsp;Weibin Hu MD ,&nbsp;Yongkai Lu PhD","doi":"10.1016/j.jaccao.2024.08.009","DOIUrl":"10.1016/j.jaccao.2024.08.009","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Page 985"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11712011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}